A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Enhertu combo cleared for use in frontline breast cancer
Enhertu combo cleared for use in frontline breast cancer
‘Zombie’ biotech buyer Xoma to acquire Generation Bio
‘Zombie’ biotech buyer Xoma to acquire Generation Bio
Argenx falters in effort to expand immune drug’s use
Argenx falters in effort to expand immune drug’s use
Sanofi MS drug hits two setbacks
Sanofi MS drug hits two setbacks
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease
How rare-disease teams can fine-tune COAs to bridge meaningful change and measurable progress
How rare-disease teams can fine-tune COAs to bridge meaningful change and measurable progress
Sobi snaps up gout drug in $950M deal for startup Arthrosi
Sobi snaps up gout drug in $950M deal for startup Arthrosi
Arcus cancels work on Gilead-partnered cancer combo after trial setback
Arcus cancels work on Gilead-partnered cancer combo after trial setback
Praxis tees up another approval filing; Geron turns to layoffs
Praxis tees up another approval filing; Geron turns to layoffs
AC Immune posts positive data for Parkinson’s immunotherapy
AC Immune posts positive data for Parkinson’s immunotherapy
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer
Lilly’s three-pronged drug puts obesity field ‘on notice’
Lilly’s three-pronged drug puts obesity field ‘on notice’
Crapo, Cassidy propose enhanced ACA subsidy alternative
Crapo, Cassidy propose enhanced ACA subsidy alternative
Prolynx banks $70M for longer-lasting obesity drugs
Prolynx banks $70M for longer-lasting obesity drugs
FDA approves first drug in National Priority Voucher program
FDA approves first drug in National Priority Voucher program
A former Roivant spinout bets on AI-designed drugs for immune conditions
A former Roivant spinout bets on AI-designed drugs for immune conditions
Novartis notches another win for drug acquired in MorphoSys deal
Novartis notches another win for drug acquired in MorphoSys deal
Pfizer dips into China for another try at an obesity pill
Pfizer dips into China for another try at an obesity pill
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page